Free Online CME

Clinical Management of Myeloid Malignancies:
The Coming of Age of Targeted Therapies

Print this Content

 

Clinical Management of Myeloid Malignancies: The Coming of Age of Targeted Therapies online series will provide an in-depth and up-to-date review of research related to the biology, prognosis, natural history, and therapeutic management of patients with myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and myeloid malignancies.

Webcasts

Phillip Scheinberg, MD
Clinical Management of Myeloid Malignancies Cases
Angela Fleischman, MD, PhD; Lukasz Gondek, MD, PhD; Alan List, MD; Uwe Platzbecker, MD; Phillip Scheinberg, MD; Eytan Stein, MD
Release date:
Expiration date:
Estimated Time: 15 minutes
Type:  Webcast
Technical Requirements: None
Specialty: Hematology/Oncology
Phillip Scheinberg, MD
Release date: January 27, 2020
Expiration date: January 27, 2022
Estimated Time: 30 minutes
Type:  Webcast
Technical Requirements: None
Specialty: Hematology/Oncology
Release date: January 27, 2020
Expiration date: January 27, 2022
Estimated Time: 30 minutes
Type:  Webcast
Technical Requirements: None
Specialty: Hematology/Oncology
Release date: January 27, 2020
Expiration date: January 27, 2022
Estimated Time: 30 minutes
Type:  Webcast
Technical Requirements: None
Specialty: Hematology/Oncology
Release date: January 27, 2020
Expiration date: January 27, 2022
Estimated Time: 15 minutes
Type:  Webcast
Technical Requirements: None
Specialty: Hematology/Oncology
Myeloproliferative Neoplasms
Angela Fleischman, MD, PhD
Release date: January 27, 2020
Expiration date: January 27, 2022
Estimated Time: 30 minutes
Type:  Webcast
Technical Requirements: None
Specialty: Hematology/Oncology
BMT in Myeloid Malignancies
Uwe Platzbecker, MD
Release date: January 27, 2020
Expiration date: January 27, 2022
Estimated Time: 30 minutes
Type:  Webcast
Technical Requirements: None
Specialty: Hematology/Oncology

Series Learning Objectives

  • Describe genomic-based approaches to the management of patients with acute myeloid leukemia and high-risk myelodysplastic syndromes

  • Diagnose clonal hematopoiesis of indeterminate potential and select treatment options for these patients

  • Formulate appropriate evaluation and management strategies for patients with aplastic anemia and other bone marrow failure conditions

  • Identify the indications and the pros and cons of different strategies for bone marrow transplant in patients with myeloid malignancies

  • List the pharmacologic profiles, efficacy and side effect data, and indications for recently FDA-approved pharmaceuticals and summarize their use in clinical practice

  • Present an in-depth review of myeloproliferative neoplasms, risk stratification, prognostic implications, and treatment options

  • Summarize changes in the treatment landscape for patients with low-risk myelodysplastic syndromes

Target Audience

This educational activity is designed for an international audience including medical oncologists/hematologists, clinical and translational researchers, and other physicians and allied health care professionals treating patients with MDS and other bone marrow failure diseases. In addition, members of patient advocacy groups will benefit from this program.

Activity Director

Betty Hamilton, MD    
Department of Hematology and Medical Oncology    
Taussig Cancer Institute    
Cleveland Clinic    
Cleveland, OH

This CME activity was produced by the Cleveland Clinic Foundation Center for Continuing Education, Cleveland Clinic’s Taussig Cancer Institute and Aplastic Anemia & MDS International Foundation.